<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000148" GROUP_ID="PREG" ID="325799081020094744" MERGED_FROM="" MODIFIED="2010-05-31 18:59:50 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Short title (no longer in use): Nutrients for impaired fetal growth&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-05-06 08:49:24 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0024" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2010-05-31 18:59:50 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Maternal nutrient supplementation for suspected impaired fetal growth</TITLE>
<CONTACT MODIFIED="2010-05-31 18:59:50 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-05-31 18:59:50 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>gjh@global.co.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-05-05 13:50:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 11/11/04&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 8/30/04&lt;/p&gt;&lt;p&gt;Reformatted: 8/11/99&lt;/p&gt;" NOTES_MODIFIED="2010-05-05 13:50:52 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1995"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-23 14:43:40 +0100" MODIFIED_BY="Lynn Hampson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-04-23 14:43:40 +0100" MODIFIED_BY="Lynn Hampson">
<DATE DAY="31" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-04-23 14:43:11 +0100" MODIFIED_BY="Lynn Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-23 14:43:11 +0100" MODIFIED_BY="Lynn Hampson">
<DATE DAY="13" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-04-23 14:43:08 +0100" MODIFIED_BY="Lynn Hampson">
<DATE DAY="31" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>December 2007<BR/>We updated the search and identified and evaluated two new studies (Chen 2005; Biswas 2006). We excluded Biswas 2006 because of the unclarity of the study design. The included study (Chen 2005) compared different modes of delivery of a nutrient, resulting in addition of a new comparison. Data were included for four previously unreported fetal outcomes. The additions did not change the conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-02-13 14:53:20 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="31" MONTH="8" YEAR="2004"/>
<DESCRIPTION>
<P>August 2004<BR/>We updated the search and identified and evaluated two new studies (Guo 2002; Huang 1999). We excluded both because the selection of the groups is unclear.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-02-13 14:53:57 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="31" MONTH="3" YEAR="2002"/>
<DESCRIPTION>
<P>March 2002<BR/>We updated the search and identified and evaluated three new studies. We excluded two because the interventions were given to healthy women and one because there was no randomization.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>HRP-UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>UK Cochrane Centre, NHS R&amp;D Programme, Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Effective Care Research Unit, University of the Witwatersrand, East London/Johannesburg</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-06 08:49:24 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-02-13 14:57:21 +0000" MODIFIED_BY="Sonja Henderson">
<TITLE MODIFIED="2008-02-13 14:56:46 +0000" MODIFIED_BY="Sonja Henderson">Maternal nutrient supplementation for suspected impaired fetal growth</TITLE>
<SUMMARY_BODY MODIFIED="2008-02-13 14:57:21 +0000" MODIFIED_BY="Sonja Henderson">
<P>Too little evidence to show whether extra carnitine, solcoseryl, glucose or galactose for pregnant women benefits babies in the womb who are smaller than expected.</P>
<P>Babies growing more slowly than expected in the womb (impaired fetal growth) may be receiving too few nutrients from their mothers. Some nutrients thought to improve an unborn baby's growth include carnitine (amino acid which releases energy from fat), solcoseryl (protein-free calf blood extract), glucose and galactose (fruit, meat and milk sugars). The review of four trials, involving 165 women, found that there is too little evidence to show whether the baby's growth improves when a pregnant woman supplements her intake of these nutrients by mouth or injection. More research is needed into the effects of pregnant women supplementing their diets with these nutrients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-05-05 13:52:17 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>One way of attempting to improve fetal growth has been nutrient supplementation for the mother when fetal growth is impaired. Different nutrients such as carbohydrates and amino acids have been suggested as treatments for impaired fetal growth. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of nutrient administration for suspected fetal growth impairment on fetal growth and perinatal outcome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-04-23 14:44:16 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Acceptably controlled trials of nutrient administration for suspected impaired fetal growth compared to placebo or no treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We assessed trial quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-05-05 13:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies, involving 165 women, were included. The trials were small or had methodological limitations, or both. Carnite was associated with shorter pregnancy duration after enrolment (mean difference -2.12, 95% confidence interval -3.58 to -0.66 weeks). Intraamniotic administration of nutrients was related to higher birthweight (2575 g, standard deviation (SD) 780) as compared to intravenous administration (2080 g SD 457). No other differences were found.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to evaluate the use of nutrient therapy for suspected impaired fetal growth. The studies were too small to assess clinical outcomes adequately.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-05-06 08:49:24 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-02-13 15:19:30 +0000" MODIFIED_BY="Sonja Henderson">
<P>Impaired fetal growth is the failure of a newborn to achieve its genetically determined growth potential, which may cause death as well as short- or long-term childhood morbidity. It has been reported that 3% to 10% of neonates are small for corresponding gestational age and an estimated 30% of this is due to impaired fetal growth. The remaining 70% is due to constitutional factors such as maternal ethnicity, parity, weight and height (<LINK REF="REF-Lin-1998" TYPE="REFERENCE">Lin 1998</LINK>). The condition occurs with limited flow of nutrients or oxygen, or both, from mother to fetus as a result of fetal causes (e.g. chromosomal abnormalities, congenital malformations), placental factors (e.g. small placenta), or maternal factors (e.g. malnutrition, vascular/renal disease, drugs or other metabolic conditions) (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>).</P>
<P>Ultrasound evaluation of the fetus by measuring the abdominal circumference, head circumference, length of upper leg and interpreting these using standardised formulae allows the clinician to estimate the fetal weight, to relate this to the gestational age and to follow the growth progress. Ultrasound evaluation also allows to some extent to estimate the timing and the cause of the impairment. Symmetrical growth of the fetus is generally due to early problems such as chromosomal abnormalities, drugs, chemical agents or infection. Asymmetric growth usually results from inadequacy of substrates the fetus needs particularly later in pregnancy (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>). In low-income settings where early pregnancy ultrasound is not available, fetal growth can be monitored by serial symphysis fundus measurements. However, there is no proven effective treatment that can be applied once growth impairment is diagnosed. In general, when no apparent congenital abnormality exists, management is conservative by frequent growth measurements, smoking cessation if the mother smokes and early delivery when the fetus is thought be mature enough to survive outside the womb.</P>
<P>The outcomes of impaired growth are variable and usually related to the specific cause. For example, if the growth impairment is due to chromosomal anomalies or congenital abnormalities, the fetus is more at risk of a perinatal death. Other short-term outcomes may be moderate to mild metabolic problems (hypoglycemia, polycythemia, meconium aspiration, etc) due to the chronic oxygen and nutrient deprivation. Depending on the severity and the duration of the condition, long-term outcomes may differ from normal to small decreases in IQ to an increased risk of cerebral palsy (<LINK REF="REF-Bernstein-2000" TYPE="REFERENCE">Bernstein 2000</LINK>).</P>
<P>Because impaired fetal growth is characterised by hypoxemia, acidemia, hypoglycemia and other metabolic abnormalities (<LINK REF="REF-Economides-1993" TYPE="REFERENCE">Economides 1993</LINK>), it is tempting to try to improve fetal outcome by nutrient supplements. Supplementation with nutrients such as glucose, galactose and amino acids, however, may be potentially dangerous for the fetus. Increasing the maternal-fetal glucose gradient by intravenous glucose infusion, for example, has been shown to cause fetal acidaemia (<LINK REF="REF-Harding-1992" TYPE="REFERENCE">Harding 1992</LINK>). It is therefore important to review the evidence with regard to the benefits and risks of maternal nutrient supplementation in pregnancies with fetal growth impairment.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects on fetal growth and perinatal outcome of nutrient administration for suspected impaired fetal growth.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-05-06 08:49:24 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-05-06 08:49:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All acceptably controlled evaluations of nutrient administration for suspected impaired fetal growth.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women with suspected impaired fetal growth.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any nutrient administered to the mother oral, parenterally or by amnioinfusion to the amniotic cavity, for the purpose of promoting fetal growth. The nutrients could be in the form of micronutrients (e.g. aminoacids, minerals, vitamins) or macronutrients (e.g. glucose, energy supplements).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-05-06 08:49:24 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-05-06 08:49:24 +0100" MODIFIED_BY="[Empty name]">
<P>Fetal growth, perinatal mortality, neonatal morbidity, adverse effects on the mother and neonate.</P>
</CRIT_OUTCOMES_PRIMARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-04-23 14:45:02 +0100" MODIFIED_BY="Lynn Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2010-04-23 14:45:02 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (March 2010). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>We evaluated trials under consideration for methodological quality and appropriateness for inclusion, without consideration of their results. A quality score for concealment of allocation was assigned to each trial using the criteria described in <LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>. </P>
<P>(A) Adequate concealment of the allocation;<BR/>(B) unclear whether adequate concealment of the allocation;<BR/>(C) inadequate concealment of allocation;<BR/>(D) no concealment of allocation.</P>
<P>Whether or not an 'intention-to-treat' analysis was done in the primary study was examined. There were no language preferences in the review. </P>
<P>We extracted and processed included trial data as described in <LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-05-05 13:54:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-05-05 13:53:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See</I> table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-05 13:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>The study by <LINK REF="STD-Herre-1976" TYPE="STUDY">Herre 1976</LINK> is methodologically sound in terms of being a double-blind, placebo-controlled study, but the numbers studied are small.</P>
<P>In the <LINK REF="STD-Genger-1988" TYPE="STUDY">Genger 1988</LINK> trial, allocation was by birth dates (first half of the month, study, and second half, control group) which indicates the possibility of selection bias; no placebos were used and the outcome assessments were not blinded. The sample size is small.</P>
<P>
<LINK REF="STD-Viehweg-1987" TYPE="STUDY">Viehweg 1987</LINK> gave no details of the randomization procedure and there was no blinding.</P>
<P>
<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> reported no details of the randomization procedure.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-05-05 13:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies, involving 165 women, were included.</P>
<P>In the double-blind placebo-controlled study of Herre et al (<LINK REF="STD-Herre-1976" TYPE="STUDY">Herre 1976</LINK>), intravenous administration of protein-free calf blood extract (Solcoseryl) was associated with a significant increase in 24 hour urinary oestrogen excretion (P &lt; 0.02). The study is too small for meaningful estimation of any effects on clinical outcomes.</P>
<P>In the <LINK REF="STD-Genger-1988" TYPE="STUDY">Genger 1988</LINK> trial, carnitine was administered orally for two weeks (first week 2 g/day, second week 1 g/day) to 15 women diagnosed as having mild to moderate placental insufficiency. Eleven showed improvement, four had no change but one deteriorated, compared with eight, two and five in the control group. Carnitine was associated with shorter pregnancy duration after enrolment (mean difference -2.12, 95% confidence interval -3.58 to -0.66 weeks). No other differences were statistically significant, though meaningful differences may have been missed because of the small sample size.</P>
<P>
<LINK REF="STD-Viehweg-1987" TYPE="STUDY">Viehweg 1987</LINK> randomized women with suspected impaired fetal growth to bedrest, intravenous glucose or oral galactose treatments. The number of small-for-gestational age (birthweight less than 10th centile) infants were similar in all three groups. The small numbers studied had power to demonstrate only very large differences.</P>
<P>
<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> randomized women with impaired fetal growth to either intravenous or intra-amniotic administration of amino acids. The mean birthweight of the babies of women who had intra-amniotic administration of amino acids was significantly higher (2575 g standard deviation (SD) 780) as compared to those that received intravenous aminoacids (2080 g SD 457). Other fetal outcome measures showed similar effects in favour of intra-amniotic administration group: femur length (5.8 cm SD 0.9 versus 4.9 cm SD 1.0); biparietal diameter (7.4 cm SD 1.5 versus 5.5 cm SD 1.1); and abdominal circumference (83.7 cm SD 17.4 versus 67.1 cm SD 16.3).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-05-05 13:54:55 +0100" MODIFIED_BY="[Empty name]">
<P>Nutrient supplementation to enhance fetal growth has been investigated with several nutrients such as carnitine, calf blood extract, amino acid and glucose solutions. Although the results of two out of four included trials show some benefit in terms of 'proxy' outcomes studied, the sample sizes were too small too assess clinical outcomes adequately. One study examining the effect of nutrient supplementation according to delivery mode was also too small to reach a conclusion despite the reported effect of intra-amniotic administration. It is imperative that nutritional supplementation to enhance fetal growth is investigated through well-designed, randomized controlled trials with adequate sample size and clinical endpoints.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The trials examined in this review are inadequate to elucidate the effectiveness of nutrient therapy for suspected impaired fetal growth. </P>
<P>There is inadequate evidence from the studies examined in this review to support the routine use of nutrient therapy for suspected impaired fetal growth in clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for further research to evaluate the effectiveness and risks of nutrient therapy for suspected impaired fetal growth.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-02-13 15:27:02 +0000" MODIFIED_BY="Sonja Henderson">
<P>Justus Hofmeyr wrote the original review for the Cochrane Pregnancy and Childbirth Database. Metin Gülmezoglu was responsible for earlier updates of the review. Lale Say contributed to earlier updates by checking the data entries and revising the text of the review. LS is now the guarantor for the review and prepared the 2008 update. For all versions of the review, at least two authors did the data extraction and all contributed or commented on the text.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-02-13 15:21:01 +0000" MODIFIED_BY="Sonja Henderson">
<STUDIES MODIFIED="2008-02-13 15:21:01 +0000" MODIFIED_BY="Sonja Henderson">
<INCLUDED_STUDIES MODIFIED="2008-02-13 15:21:01 +0000" MODIFIED_BY="Sonja Henderson">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2008-02-13 15:21:01 +0000" MODIFIED_BY="Sonja Henderson" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-02-13 15:21:01 +0000" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen H, Wang X, Liu H, Wang T</AU>
<TI>Maternal blood and amniotic fluid insulin-like growth factor detection and amniotic cavity drug delivery for early diagnosis and management of fetal growth restriction</TI>
<SO>Journal of the First Military Medical University</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1158-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genger-1988" NAME="Genger 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;[4639]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genger H, Enzelsberger H, Salzer H</AU>
<TI>Carnitine treatment for placental insufficiency - initial experience</TI>
<TO>Carnitin als Therapie der Plazentainsuffizienz - Erste Erfahrungen</TO>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1988</YR>
<VL>92</VL>
<PG>155-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herre-1976" NAME="Herre 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;[1146]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herre HD, Kyank H, Adomssent S, Wilken HP</AU>
<TI>Effect of the protein-free calf-blood extract (Solcoseryl) on the excretion of oestrogens in chronic placental insufficiency</TI>
<TO>Einfluss eines proteinfreien Kaelberblutextraktes (Solcoseryl) auf die Oestrogenausscheidung bei chronischer Plazentainsuffizienz</TO>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1976</YR>
<VL>98</VL>
<PG>212-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viehweg-1987" NAME="Viehweg 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;[9542]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruckhaberle Von K-E, Petzold J, Viehweg B, Ruckhaberle B, Robel R, Langanke D et al</AU>
<TI>Therapeutic efforts and prenatal modification of selected disordered fetomaternal relations</TI>
<TO>Therapeutische bemühungen um praepartale beeinflussung ausgewaehlter gestoerter fetomaternaler beziehungen</TO>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1985</YR>
<VL>107</VL>
<PG>803-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[8951]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Viehweg B, Ruckhaberle K-E, Zimmermann G, Beyreiss K, Petzold J, Forberg J</AU>
<TI>For the treatment of suspected intrauterine fetal growth retardation</TI>
<TO>Zur therapie bei verdacht auf intrauterine fetale retardierung</TO>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1987</YR>
<VL>109</VL>
<PG>818-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernaschek-1984" NAME="Bernaschek 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Bernaschek G, Spernol R, Schaller A. The effect of calf blood dialysate on the excretion of estriol in placental insufficiency (translation). Wiener Klinische Wochenschrift 1984;96:279-82&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernaschek G, Spernol R, Schaller A</AU>
<TI>The effect of calf blood dialysate on the excretion of estriol in placental insufficiency</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1984</YR>
<VL>96</VL>
<PG>279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biswas-2006" NAME="Biswas 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Biswas B. Effect of glutamine supplementation on prevention and management of idiopathic foetal growth restriction [abstract]. 49th All India Congress of Obstetrics and Gynaecology; 2006 Jan 6-9; Cochin, Kerala State, India 2006:37&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Biswas B</AU>
<TI>Effect of glutamine supplementation on prevention and management of idiopathic foetal growth restriction [abstract]</TI>
<SO>49th All India Congress of Obstetrics and Gynaecology; 2006 Jan 6-9; Cochin, Kerala State, India</SO>
<YR>2006</YR>
<PG>37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-1977" NAME="Chang 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;[1225]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang A, Abell D, Beischer N, Wood C</AU>
<TI>Trial of intravenous therapy in women with low urinary estriol secretion</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1977</YR>
<VL>127</VL>
<PG>793-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chimura-1982" NAME="Chimura 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;[9017]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chimura T, Funayama T, Mitsui T, Kaneko N</AU>
<TI>Effect of infusion therapy on intrauterine fetal growth retardation</TI>
<SO>Acta Obstetrica et Gynaecologica Japonica</SO>
<YR>1982</YR>
<VL>34</VL>
<PG>551-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2002" NAME="Guo 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo XY, Lei HZ, Weng SW, Jing Y, Tong XT</AU>
<TI>Clinical study of L-arginine in treating intrauterine growth retardation of fetus</TI>
<SO>Guangdong Medical Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>8</NO>
<PG>864-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00445600"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1999" NAME="Huang 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang G, Shu Y, Wangyun Y</AU>
<TI>Clinical study on effect of Chinese herbal medicine for supplementing kidney and qi and activating blood circulation in treating intrauterine growth retardation of fetus</TI>
<SO>Chung Kuo Chung Hsi I Chieh Ho Tsa Chih</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>466-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ling-1996" NAME="Ling 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ling CD, Zhang ZJ, Chen ZL</AU>
<TI>Studies on nutritional effects of traditional Chinese tonics with strengthened nutrients on pregnant women and rats</TI>
<SO>Chung Kuo Chung Hsi I Chieh Ho Tsa Chih</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>5</NO>
<PG>270-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mesaki-1980" NAME="Mesaki 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;[9018]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mesaki N, Kubo T, Iwasaki H</AU>
<TI>A study of the treatment for intrauterine growth retardation</TI>
<SO>Acta Obstetrica et Gynaecologica Japonica</SO>
<YR>1980</YR>
<VL>32</VL>
<PG>879-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavlovich-1999" NAME="Pavlovich 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Pavlovich SV, Burlev VA, Vikhliaeva EM. The effect of n-3 polyunsaturated fatty acids on the lipid spectrum indices in the 2nd-3rd pregnancy trimesters (translation). Eksperimentalnaia i Klinicheskaia Farmakologiia 1999;62(6):35-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavlovich SV, Burlev VA, Vikhliaeva EM</AU>
<TI>The effect of n-3 polyunsaturated fatty acids on the lipid spectrum indices in the 2nd-3rd pregnancy trimesters</TI>
<SO>Eksperimentalnaia i Klinicheskaia Farmakologiia</SO>
<YR>1999</YR>
<VL>62</VL>
<NO>6</NO>
<PG>35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sood-1994" NAME="Sood 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;[8825]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sood M, Gulati A, Agarwal N, Faridi MMA, Prabhu KM</AU>
<TI>Fetal feeding by amnioinfusion: an Indian experience [abstract]</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>116</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xing-1994" NAME="Xing 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;[8644]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xing A, Baolin W, Weiyue Z</AU>
<TI>Biochemical effects of maternal intravenous and intra-amniotic infusion of amino-acids on fetal blood</TI>
<SO>Journal of West China University of Medical Sciences</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>98-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-1993" NAME="Xu 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;[8046]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu Y</AU>
<TI>Ensure treatment for IUGR</TI>
<SO>Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao (China)</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>1</NO>
<PG>63-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1997" NAME="Zhang 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;[9926]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L</AU>
<TI>The effects of essential fatty acids preparation in the treatment of intrauterine growth retardation</TI>
<SO>American Journal of Perinatology</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>9</NO>
<PG>535-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Alderson-2004" NAME="Alderson 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins JPT, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.2.2 (updated March 2004)</TI>
<SO>In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-2000" NAME="Bernstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A</AU>
<TI>Morbidity and mortality among very low birth weight infants with intrauterine growth restriction. The Vermont Oxford Network</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Economides-1993" NAME="Economides 1993" TYPE="BOOK_SECTION">
<AU>Economides DL, Nicolaides KH</AU>
<TI>Cordocentesis in the investigation of fetal oxygenation and metabolism</TI>
<SO>Ultrasound in obstetrics and gynecology</SO>
<YR>1993</YR>
<PG>433</PG>
<ED>Chervenak FA, Isaacson GC, Campbell S</ED>
<PB>Little, Brown and Company</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harding-1992" NAME="Harding 1992" TYPE="JOURNAL_ARTICLE">
<AU>Harding JE, Owens JA, Robinson JS</AU>
<TI>Should we try to supplement the growth retarded fetus? A cautionary tale</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<PG>707-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-1998" NAME="Lin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lin C, Santolaya-Forgas J</AU>
<TI>Current concepts of fetal growth restriction: Part 1. Causes, classification, and pathophysiology</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>6</NO>
<PG>1044-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resnik-2002" NAME="Resnik 2002" TYPE="JOURNAL_ARTICLE">
<AU>Resnik R</AU>
<TI>Intrauterine growth restriction</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>3</NO>
<PG>490-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-05-05 13:55:38 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-05-05 13:55:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-05-05 13:55:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_METHODS>
<P>Randomized. No further details given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 women with fetal growth restriction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-05 13:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment group received intra-amniotic and control group intravenous administration of amino acid compound.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-05 13:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>Birthweight; femur length; biparietal diameter; abdominal circumference.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 15:15:04 +0000" MODIFIED_BY="Sonja Henderson">
<P>Small sample size for any conclusion. Assessment of different delivery modes of nutrient; no placebo group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-05 13:55:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genger-1988">
<CHAR_METHODS>
<P>Allocation according to birth dates of the women (1-15th of the month, study, 16-30th control).<BR/>No placebos were used.<BR/>There was no blinding at allocation, conduct and assessment of outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 (15 study and 15 control) women diagnosed as having mild to moderate placental insufficiency (fetuses 1-3 weeks behind in growth).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-05 13:55:38 +0100" MODIFIED_BY="[Empty name]">
<P>The study group received 2 x 1 gm oral carnitine daily for 1 week and 1 x 1 gm daily for a second week.<BR/>The control group were untreated.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-13 15:16:01 +0000" MODIFIED_BY="Sonja Henderson">
<P>Enrolment to delivery interval; gestational age at delivery; operative delivery; birthweight; Apgar scores; birthweight percentile.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Methodology is weak with no blinding at any stage.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 15:16:26 +0000" MODIFIED_BY="Sonja Henderson" STUDY_ID="STD-Herre-1976">
<CHAR_METHODS MODIFIED="2008-02-13 15:15:23 +0000" MODIFIED_BY="Sonja Henderson">
<P>Double-blind, placebo-controlled study, but the numbers studied are small.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 women diagnosed as having chronic placental insufficiency in late pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>16 women received Solcoseryl and 15 women received placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-13 15:16:26 +0000" MODIFIED_BY="Sonja Henderson">
<P>Urinary oestriol secretion; low birthweight; perinatal mortality; mean gestational age at delivery; mean duration in the study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The sample size is too small to reach any meaningful conclusions.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 15:16:37 +0000" MODIFIED_BY="Sonja Henderson" STUDY_ID="STD-Viehweg-1987">
<CHAR_METHODS>
<P>Randomized. No further details given.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>45 women (randomized into 3 groups of 15) with clinical and ultrasonographic suspicion of impaired fetal growth.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>10% glucose 2000 ml/daily intravenous infusion versus oral 10% galactose 500 ml/daily versus control (bed rest).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-13 15:16:37 +0000" MODIFIED_BY="Sonja Henderson">
<P>Fetal growth (birthweight &lt; 10th centile); fetal heart rate monitoring tests; ultrasound measurements.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-02-13 15:35:19 +0000" MODIFIED_BY="Sonja Henderson" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bernaschek-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Calf blood extract was administered to women with impaired fetal growth. The authors state that urinary oestriol excretion increased following administration of calf blood extract. However, there is no randomly allocated control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-13 15:35:19 +0000" MODIFIED_BY="Sonja Henderson" STUDY_ID="STD-Biswas-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-13 15:35:19 +0000" MODIFIED_BY="Sonja Henderson">
<P>No evidence of randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chang-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chimura-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no evidence of any randomized comparison in this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guo-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study compares l-arginine to undefined aminoacids in three groups of women (30 in arginine, 20 in amino acid, and 10 in control groups). It is reported that 50 women were randomized to arginine and amino acid groups, but not clear how randomization was made and women were assigned to these 3 groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares the effect of Chinese Herbal Medicine to amino acid in 2 groups of women with IUGR. The selection of groups is not clear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ling-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized trial of a mixture of Chinese tonics strengthened with other nutrients (iron, zinc, calcium) given to healthy women to see the effects on fetal growth.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mesaki-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no evidence of any randomized comparison between treated (amino acid and glucose) and untreated (control) groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pavlovich-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a randomized controlled trial of 60 pregnant women at risk of placental insufficiency given picasol (n-3 polyunsaturated fatty acids) or placebo. The report is in Russian and the article is currently excluded as prophylactic administration is not within the scope of this review. Attempts will be made to translate the full report to ensure that the assessment based on the abstract is correct.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sood-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study has been excluded for the time being until a full report is published. Currently, it is only available as an abstract (published in 1994). There is inadequate information on the methodological quality (although it is mentioned that the study was 'randomized') and inadequate data for any meaningful extraction. Briefly, pregnant women with severe impaired fetal growth were allocated to either maternal hyperalimentation or 5% amino acid solution for promotion of fetal growth.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xing-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>58 healthy women undergoing caesarean section were randomly divided into intravenous, intra-amniotic and control groups. The umbilical blood pH, pO2 and pCO2 levels were similar in the 3 groups. No clinically relevant outcomes were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xu-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women with suspected fetal growth impairment were given either Ensure or amino acid treatment. There is no evidence of any randomized comparison between the 2 groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study does not appear to be a randomized controlled trial. A group of randomly selected women with impaired fetal growth received oxygen inhalation, vitamins B and E, 10% glucose and 7% amino acid infusions daily. The intervention group received 500 ml of 10% intralipid emulsion (containing linoleic acid, linolenic acid and oleic acid) alternating with the amino acid infusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>IUGR: intrauterine growth retardation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Genger-1988">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Herre-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Viehweg-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-05-05 13:56:50 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Calf blood extract versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4656559592707183" CI_START="0.19580979704211612" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.16603203815956497" LOG_CI_START="-0.7081655827326409" LOG_EFFECT_SIZE="-0.27106677228653797" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.22418636599306596" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="1.2154714183388171">
<NAME>Low weight for gestational age (&lt; 5th centile)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4656559592707183" CI_START="0.19580979704211612" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.16603203815956497" LOG_CI_START="-0.7081655827326409" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="67" O_E="0.0" SE="0.5135080098600957" STUDY_ID="STD-Herre-1976" TOTAL_1="16" TOTAL_2="15" VAR="0.2636904761904762" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.627555752732273" CI_START="0.00976760341308864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18823529411764706" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5596140959320774" LOG_CI_START="-2.010211982048814" LOG_EFFECT_SIZE="-0.725298943058368" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.2685763330867653" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.00000000000001" Z="1.1063470937584123">
<NAME>Perinatal mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.627555752732273" CI_START="0.00976760341308864" EFFECT_SIZE="0.18823529411764706" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5596140959320774" LOG_CI_START="-2.010211982048814" LOG_EFFECT_SIZE="-0.725298943058368" ORDER="68" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Herre-1976" TOTAL_1="16" TOTAL_2="15" VAR="2.2786764705882354" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Carnitine versus no treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6564348158880946" CI_START="-3.5835651841119054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.12" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.004524914059786642" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="2.8390424234819807">
<NAME>Pregnancy duration after enrolment (weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6564348158880946" CI_START="-3.5835651841119054" EFFECT_SIZE="-2.12" ESTIMABLE="YES" MEAN_1="5.18" MEAN_2="7.3" ORDER="69" SD_1="2.04" SD_2="2.05" SE="0.7467306520203029" STUDY_ID="STD-Genger-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6250428207282532" CI_START="-1.825042820728256" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3370809938686331" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.9599488040956382">
<NAME>Gestational age at delivery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6250428207282532" CI_START="-1.825042820728256" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="38.4" MEAN_2="39.0" ORDER="70" SD_1="1.5" SD_2="1.9" SE="0.6250333324444919" STUDY_ID="STD-Genger-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.965261095458803" CI_START="0.35804316099383415" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6680315801223178" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.4288511132734677">
<NAME>Operative delivery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="71" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Genger-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="427.2827804268485" CI_START="-269.88278042684885" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="78.69999999999982" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6581247641281327" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.4425036870565431">
<NAME>Birthweight (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="427.2827804268485" CI_START="-269.88278042684885" EFFECT_SIZE="78.69999999999982" ESTIMABLE="YES" MEAN_1="2722.0" MEAN_2="2643.3" ORDER="72" SD_1="435.1" SD_2="534.0" SE="177.85162542599005" STUDY_ID="STD-Genger-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1092302710912942E-33" CI_END="14.667047204122266" CI_START="-11.467047204122277" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.599999999999994" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.8103390938531819" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.2399886008121848">
<NAME>Birthweight centile</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.667047204122266" CI_START="-11.467047204122277" EFFECT_SIZE="1.5999999999999943" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="32.2" ORDER="73" SD_1="18.8" SD_2="17.7" SE="6.666983325812858" STUDY_ID="STD-Genger-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.886625251644639E-32" CI_END="1.1921100138533207" CI_START="-0.39211001385332006" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4000000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.3222996088990635" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.00000000000001" Z="0.9897433186107877">
<NAME>Apgar score 1 minute</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1921100138533207" CI_START="-0.39211001385332" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="8.2" ORDER="74" SD_1="0.7" SD_2="1.4" SE="0.40414518843273806" STUDY_ID="STD-Genger-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Glucose versus bed rest</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9193150074463587" CI_START="0.6432335997190768" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2831462591380043" LOG_CI_START="-0.191631278016654" LOG_EFFECT_SIZE="0.04575749056067514" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7055868208865963" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.37778970782537513">
<NAME>Small-for-gestational age (birthweight &lt; 10th centile)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9193150074463585" CI_START="0.6432335997190769" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.28314625913800423" LOG_CI_START="-0.19163127801665392" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="75" O_E="0.0" SE="0.2788866755113585" STUDY_ID="STD-Viehweg-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.07777777777777777" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Galactose versus bed rest</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5363827814901816" CI_START="0.3937418974574756" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.18649943130640095" LOG_CI_START="-0.40478837015653707" LOG_EFFECT_SIZE="-0.10914446942506803" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.46932941302497244" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.7235705815530002">
<NAME>Small-for-gestational age (birthweight &lt; 10th centile)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5363827814901816" CI_START="0.3937418974574756" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.18649943130640095" LOG_CI_START="-0.40478837015653707" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="76" O_E="0.0" SE="0.3473253815011518" STUDY_ID="STD-Viehweg-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.12063492063492064" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-05-05 13:56:50 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Intra-amniotic versus intravenous administration of amino acids</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="872.758242780741" CI_START="117.24175721925889" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="495.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2008-02-13 15:29:25 +0000" MODIFIED_BY="Sonja Henderson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.010220984667982401" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="2.5682620853105806">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="872.758242780741" CI_START="117.24175721925889" EFFECT_SIZE="495.0" ESTIMABLE="YES" MEAN_1="2575.0" MEAN_2="2080.0" ORDER="77" SD_1="780.0" SD_2="457.0" SE="192.73733893094462" STUDY_ID="STD-Chen-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4621808373507406" CI_START="0.3378191626492584" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2008-02-13 15:29:35 +0000" MODIFIED_BY="Sonja Henderson" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0017026586336603376" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="99.99999999999999" Z="3.137722719967987">
<NAME>Femur length</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4621808373507406" CI_START="0.3378191626492584" EFFECT_SIZE="0.8999999999999995" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="4.9" ORDER="78" SD_1="0.9" SD_2="1.0" SE="0.2868322284415182" STUDY_ID="STD-Chen-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.6772751799951164" CI_START="1.1227248200048843" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2008-02-13 15:29:44 +0000" MODIFIED_BY="Sonja Henderson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.6594554629627728E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="4.791007955058469">
<NAME>Biparietal diameter</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6772751799951164" CI_START="1.1227248200048843" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="5.5" ORDER="79" SD_1="1.5" SD_2="1.1" SE="0.3965762565670407" STUDY_ID="STD-Chen-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="26.562833812414972" CI_START="6.637166187585043" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="16.60000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2008-02-13 15:29:53 +0000" MODIFIED_BY="Sonja Henderson" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.0010920254392062637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="99.99999999999999" Z="3.26567749256458">
<NAME>Abdominal circumference</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="26.562833812414972" CI_START="6.637166187585043" EFFECT_SIZE="16.60000000000001" ESTIMABLE="YES" MEAN_1="83.7" MEAN_2="67.1" ORDER="80" SD_1="17.4" SD_2="16.3" SE="5.083171880198068" STUDY_ID="STD-Chen-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>